News Service

late-breaking news in healthcare

FDA Expands Approval of Dupixent

June 27, 2019 News Service

On June 26, 2019, the Food and Drug Administration (FDA) approved a supplemental biologics license application (BLA) for Dupixent (dupilumab; Sanofi and Regeneron Pharmaceuticals Inc.) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). This is the first FDA-approved treatment for this indication.

FDA News Briefs for Monday, June 24, 2019

June 24, 2019 News Service

These Food and Drug Administration (FDA) developments came in last week.

FDA News Briefs for Thursday, June 20, 2019

June 20, 2019 News Service

These Food and Drug Administration (FDA) developments came in this week.

FDA News Briefs for Wednesday, June 19, 2019

June 19, 2019 News Service

These Food and Drug Administration (FDA) developments came in this week.

FDA News Briefs for Monday, June 17, 2019

June 17, 2019 News Service

These Food and Drug Administration (FDA) developments came in last week.

USPSTF Issues PrEP Recommendations for HIV Prevention

June 13, 2019 News Service

USPSTF final recommendation statement for preexposure prophylaxis (PrEP) for HIV prevention.

FDA Approves First Chemoimmunotherapy Regimen for DLBCL

June 11, 2019 News Service

The Food and Drug Administration (FDA) has approved a biologics license application (BLA) for Polivy (polatuzumab vedotin-piiq; Genentech Inc.) to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in combination with a rituximab product plus bendamustine in adult patients who received at least 2 prior therapies.

FDA News Briefs for Monday, June 10, 2019

June 10, 2019 News Service

These Food and Drug Administration (FDA) developments came in last week.

Guideline Watch

June 7, 2019 News Service

These clinical guidelines were recently released.

FDA News Briefs for Wednesday, June 05, 2019

June 5, 2019 News Service

These Food and Drug Administration (FDA) developments came in this week.